Premium
Olanzapine treatment after clozapine induced agranulocytosis
Author(s) -
Lokshin P.,
Dorfman P.,
Shoshani D.,
Wimmer P.,
Dossenbach M.,
Belmaker R. H.
Publication year - 1998
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/(sici)1099-1077(1998120)13:8<583::aid-hup33>3.0.co;2-e
Subject(s) - olanzapine , clozapine , medicine , antipsychotic , atypical antipsychotic , psychosis , schizophrenia (object oriented programming) , pediatrics , psychiatry
Clozapine is an atypical antipsychotic with a significant incidence of agranulocytosis. Olanzapine resembles clozapine structurally; however, it lacks a halogen, which has been implicated in agranulocytosis. Both agents have a similar pharmacological profile. We therefore studied olanzapine in patients with a history of clozapine‐induced agranulocytosis. Two patients with severe clozapine‐induced agranulocytosis and no benefit from classic neuroleptics were treated with olanzapine with informed consent. Psychosis improved in both patients and no hematological changes were noted. Olanzapine may be a safe treatment alternative in patients with a history of clozapine agranulocytosis. Copyright © 1998 John Wiley & Sons, Ltd.